Paradigm Biocapital Advisors’s Achieve Life Sciences ACHV Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.3M	Buy	+4,951,856	New	+$23.6M	0.61%	22

Other funds holding ACHV

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paradigm Biocapital Advisors's ACHV Position: Q2 2026 in Review

Paradigm Biocapital Advisors opened a new position in Achieve Life Sciences (ACHV) in Q2 2026: 4,951,856 shares worth $32.3M. The stake represents 0.61% of the portfolio and ranks #22 among its holdings.

89 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

Paradigm Biocapital Advisors held 4,951,856 shares of Achieve Life Sciences worth $32.3M as of Q2 2026.
Achieve Life Sciences was a new Paradigm Biocapital Advisors position in Q2 2026.
Achieve Life Sciences made up 0.61% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #22 holding.
89 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.